GleamWall
中文EN

ALLR Allarity Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1860657 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-2.7%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-3,938.3%
Net margin-4,493.7%
FCF margin-3,785.4%
EBITDA margin—

Returns

ROE-322.7%
ROA-65.5%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets108.3%
Debt / equity—
Current ratio0.91x
Interest coverage-6.83x

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-10.6%
Payout ratio—
Capex / revenue20.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$320,000$0
R&D expense$6.60M$6.10M
SG&A expense$6.32M$11.44M
Operating income-$12.61M-$27.24M
Interest expense$185,000$653,000
Pretax income-$11.23M-$24.90M
Income tax$0-$381,000
Net income-$11.23M-$24.52M
EBITDA—-$27.23M
EPS (basic)-0.78-15.65
EPS (diluted)——
Balance sheet
Cash & equivalents$14.69M$19.53M
Current assets$17.93M$22.34M
PP&E, net$330,000$309,000
Intangibles—$0
Total assets$18.26M$22.65M
Current liabilities$8.43M$10.84M
Short-term debt$0—
Total liabilities$8.43M$10.84M
Shareholders' equity$9.83M$11.81M
Shares outstanding16.08M7.30M
Cash flow statement
Operating cash flow-$14.82M-$17.35M
Capital expenditure$8,000$298,000
Free cash flow-$14.83M-$17.65M
Investing cash flow-$8,000-$298,000
Financing cash flow$10.65M$36.79M
Depreciation & amortization—$9,000
Stock-based compensation$482,000$71,000
Share buybacks$3.19M$0

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.